Okay, let's tackle this question. The patient is a 72-year-old man with a long history of urinary symptoms: difficulty starting and stopping urination, urgency, and nocturia. The prostate is enlarged but not tender. PSA is 6 ng/mL, which hasn't changed much. The key here is to figure out the most effective drug for his condition.

First, the core concept is benign prostatic hyperplasia (BPH). The symptoms align with BPH: lower urinary tract symptoms (LUTS), prostate enlargement, and stable PSA. The question is about treatment options for BPH.

The correct answer is likely an alpha-1 adrenergic blocker. These drugs relax the smooth muscle in the prostate and bladder neck, improving urine flow. Tamsulosin is a common example. They work quickly and are often first-line for mild to moderate symptoms.

Now, the options aren't listed, but typical choices for BPH include 5-alpha reductase inhibitors (like finasteride), alpha-blockers, anticholinergics, or maybe PDE5 inhibitors. The wrong options would be those that don't target the prostate's smooth muscle or aren't indicated for BPH.

Finasteride is a 5-alpha reductase inhibitor. It reduces prostate size over time but takes months to work. Since the patient has been symptomatic for 10 years and the PSA is stable (no sign of prostate cancer), maybe he needs quicker relief. So finasteride might not be the best first choice here.

Anticholinergics are for overactive bladder, which can cause urgency, but the main issue here is outflow obstruction from BPH. So they wouldn't address the primary problem. PDE5 inhibitors are for erectile dysfunction and not BPH. Beta-blockers are for hypertension, not relevant here.

The clinical pearl is that alpha-blockers are first-line for BPH symptoms due to their rapid onset, while 5-alpha reductase inhibitors are for long-term management when there's a need to reduce prostate size, especially with high PSA or large prostates. The patient's stable PSA and symptoms suggest an alpha-blocker is more appropriate now.

**Core Concept**
This question tests the pharmacological management of benign prostatic hyperplasia (BPH). BPH is characterized by prostate enlargement causing obstructive urinary symptoms, and treatment options include alpha-1 adrenergic blockers, 5-alpha reductase inhibitors, and others.

**Why the Correct Answer is Right**
The patient’s symptoms (urgency, difficulty initiating/stopping urination, nocturia) and non-tender, enlarged prostate suggest BPH. Alpha-1 adrenergic blockers (e.g., tamsulosin) are first-line for BPH. They relax prostate and bladder neck smooth muscle, reducing outlet resistance. This provides rapid symptom relief within days, making them ideal for this patient’s chronic, stable disease.

**Why Each Wrong Option is Incorrect**
**Option A:** 5-alpha reductase inhibitors (e.g., finasteride) shrink the prostate over months but are not first-line for acute symptom control.
**Option B:** Anticholinergics treat overactive bladder but worsen outflow obstruction in BPH.
**Option D:** Beta-agonists are not used in BPH; beta-blockers are contraindicated due

✓ Correct Answer: B. Finasteride (5a-reductase inhibitor)